Skip to main content
SpringerLink
Log in

Rezvilutamide: First Approval

  • Adisinsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Rezvilutamide (艾瑞恩®) is an oral, second-generation androgen receptor antagonist being developed by Jiangsu Hengrui Medicine Co., Ltd for the treatment of prostate cancer. In June 2022, rezvilutamide was approved in China for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with high tumour burden. This article summarizes the milestones in the development of rezvilutamide leading to this first approval for patients with prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. National Comprehensive Cancer Network. NCCN Guidelines version 1.2023: prostate cancer. 2022. https://www.nccn.org/. Accessed 8 Dec 2022.

  2. Gu W, Han W, Luo H, et al. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. Lancet Oncol. 2022;23(10):1249–60.

    Article  CAS  Google Scholar 

  3. Chen Y, Zhou Q, Hankey W, et al. Second generation androgen receptor antagonists and challenges in prostate cancer treatment. Cell Death Dis. 2022. https://doi.org/10.1038/s41419-022-05084-1.

    Article  Google Scholar 

  4. Shiota M, Terada N, Saito T, et al. Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients. Cancer Sci. 2020. https://doi.org/10.1111/cas.14722.

    Article  Google Scholar 

  5. Ng K, Smith S, Shamash J. Metastatic hormone-sensitive prostate cancer (mHSPC): advances and treatment strategies in the first-line setting. Oncol Ther. 2020;8(2):209–30.

    Article  Google Scholar 

  6. Kostos L, Murphy DG. Treatment options for metastatic hormone-sensitive prostate cancer. Lancet Oncol. 2022;23(10):1234–5.

    Article  CAS  Google Scholar 

  7. Jiangsu Hengrui Pharmaceutical Co Ltd. Rezvilutamide (艾瑞恩®): Chinese Prescribing information. Shanghai: Jiangsu Hengrui Pharmaceutical Co Ltd; 2022.

  8. Dai T, Xu Z, Huang L, et al. A single-centre, open-label, single-arm, fixed-sequence pharmacokinetic study of SHR3680 on repaglinide and bupropion in prostate cancer patients. Br J Clin Pharmacol. 2022. https://doi.org/10.1111/bcp.15528.

    Article  Google Scholar 

  9. Qin X, Ji D, Gu W, et al. Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial. BMC Med. 2022. https://doi.org/10.1186/s12916-022-02263-x.

    Article  Google Scholar 

  10. National Medical Products Administration. Rezvilutamide: approval notification. 2022. https://www.nmpa.gov.cn/yaowen/ypjgyw/20220629092644102.html. Accessed 9 Nov 2022.

  11. Jiangsu Hengrui Pharmaceutical Co Ltd. Hengrui Medicine's rezvilutamide tablets approved for marketing; new options for prostate cancer patients [media release]. 3 Jul 2022. https://www.hengrui.com/media/detail-223.html.

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Susan J. Keam

Authors
  1. Susan J. Keam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan J. Keam.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, and Code availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (PPTX 498 kb)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Keam, S.J. Rezvilutamide: First Approval. Drugs 83, 189–193 (2023). https://doi.org/10.1007/s40265-022-01831-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-022-01831-y

Search

Navigation